Vor Biopharma (VOR) stock

Autoimmune medicines , market cap $1.1B

Medicines for autoimmune diseases

Market cap $1.1B

$18.33

+0.38%

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#123of 291

Biotech

Checks firing

4of 14

Choppy

From 52-week high

-36.0%

Below the 200-day

VOR's Quality Score rose 3 points on Mon, Oct 26, to 1. Closed near the day's high (3 chart checks started).

Follow VOR's trial news. Pro members can get an alert when Vor Biopharma files news, and see its trials, share raises, and its CEO's filings.

Get an alert when VOR files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Why is VOR down?

Down 34% in a year while the S&P 500 rose 14%.

It filed a prospectus for an offering of shares of $100.0M on Nov 12, 2025.

Sources: Price history, Oct 23, 2026; Prospectus supplement, Nov 12, 2025

The timeline and its peers, for Pro members.

Key facts on VOR

Key facts on VOR
Holding it back	8.7 times as many shares as a year ago
Latest filing	S-3ASR, Sep 4 Registered shares for a later sale (S-3ASR)

5 more reasons behind VOR's 1, for Pro members.

VOR catalysts

Coming up

After its last 4 reports it closed -1.0% on average, higher 2 of 4 times.

3 past catalysts since 2025, with sizes and sources, for Pro members.Get in free →

What's next for VOR, and how long its cash lasts

Its trials

A trial underway: Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Phase 3 · Active · 191 people · main data estimated Mar 2027 · NCT06456580

1 more trial, 35 filings, for Pro members.

Cash runway

The company says its cash lasts into Mid-2028 (8-K, Jan 12).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Sep 4, 2026)
At-the-market share sales program (S-3ASR, filed Sep 4, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director RA CAPITAL MANAGEMENT, L.P. sold 165,150 shares on Apr 22. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Jean-Paul Kress buys or sells

For Pro members: every trade, and Jean-Paul Kress’s 6 filings and quotes.

Get an alert when VOR files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Why VOR scores 1

Below AverageChoppy, 4 of 14 chart checks firingWhat the Quality Score means

+4Chart checks 4 of 14 firing right now, one point each
−2Long-term trend below a falling 200-⁠day average, down over one year

Run-up adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on VOR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:16 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when VOR's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on VOR and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

VOR has 4 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on VOR, and all 14 on every stock.Get in free →

VOR RSI today: 41.8, below its 50-day, above its 200-day

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1441.8
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 11 sessions ago.
50-day average$20.99
The price is 12.7% below it.
200-day average$17.21
The price is 6.5% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Jul 22.
ADX 149.8
Under 25, with +DI below -DI.
Support$17.86
Swing low from Oct 7, 2.6% below the price.
Resistance$18.60
Swing high from Jan 21, 1.5% above the price.
52-week high$28.66
From Oct 28, 2025, 56.4% above the price.
52-week low$6.50
From Nov 20, 2025, 64.5% below the price.
Chart patternWedge
Lines over the Sep 22 and Oct 12 highs and under the Aug 12 and Oct 7 lows.
Bollinger Bands (20, 2)Inside
The bands run from $17.71 to $19.83.
Volume0.6x
Against its 20-day average, for the time of day.

The deep dive on VOR

What it does and how it makes money1 findingFor Pro members1 finding on what VOR does and how it makes money, for Pro members
Where it stands2 findingsIt spent $141M more than its operations brought in over the four quarters to Jun 30, 2026, after capital spending.Cash flow statements to Jun 30, 2026, filed Aug 11, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades VOR, for Pro members

4 more findings on VOR, each with its source, for Pro membersGet in free →

How VOR ranks in Biotech

VOR is #123 of 291 by Quality Score.

How VOR ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	VKTXViking Therapeutics		Open for its score
	VNDAVanda Pharmaceuticals		Open for its score
	VRDNViridian Therapeutics		Open for its score
	VRTXVertex Pharmaceuticals		Open for its score
123	VORVor Biopharma	4/14	1

When does VOR report earnings, and what happens after?

Expected to report Thu Nov 12 (in 17 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

-4.7%+1.5%-3.4%

Jan 12Mar 30May 13

Reported	When	Gap	Reaction	5 sessions
May 13, 2026Before open	Before open	-1.5%	-3.4%	-14.2%
Mar 30, 2026Before open	Before open	+1.2%	+1.5%	+12.4%
Jan 12, 2026No time given	No time given	+0.1%	-4.7%	+24.4%

VOR closed higher after 2 of its last 4 reports.

All 4 reports, and VOR's Quality Score going into each

VOR share count over time

Shares: 8.7 times the count a year ago (to Jun 30).

Shares of VOR outstanding, as filed
Shares outstanding	As of
59.2M	Aug 6, 2026
54.2M	May 7, 2026
48.8M	Mar 23, 2026
10.4M	Nov 7, 2025

Offerings, shelves, and splits of VOR, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Sep 4, 2026
Registered shares for a later sale (S-3)	Apr 27, 2026
Registered shares for a later sale (S-3)	Jan 29, 2026
Raised $100M in a sale of shares, about 9% of its market value	Nov 12, 2025

4 more offerings on file, for Pro members.

Who is trading VOR

VOR insider trades

One insider sold $4K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellRa Capital Management, L.P.$4K10% ownerat $19.75 on Jul 16, filed Jul 21

SellRa Capital Management, L.P.10% owner$4Kat $19.75 on Jul 16, filed Jul 21

VOR's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Sandesh MahatmeCFO

See insider trades by person

Which ETFs hold VOR?

In ETFs: VOR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

76 employeesBoston, MAvorbio.com

VOR's score card

Vor Biopharma (VOR): Quality Score 1, Below Average, #123 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn VOR's score around: 7 things
8 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJul 21Ra Capital Management, L.P. sold VOR$4K at $19.75, filed Jul 21

Alerts are optional.

See VOR's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: VOR's Quality Score is 1 (Below Average), #123 of 291 in Biotech. Insiders sold $4K in the last 6 months (Form 4).

Is VOR a good stock to buy? What its Quality Score says

VOR scores 1 today, which Breakaway calls Below Average. It is #123 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 34% in a year while the S&P 500 rose 14%. Shares: 8.7 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is VOR's Quality Score?

VOR scores 1 today, which Breakaway calls Below Average (0 to 5). That is #123 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VOR's 1.

Are insiders buying VOR?

One insider sold $4K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Ra Capital Management, L.P., 10% owner, who sold $4K on Jul 16.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.